Program
zeltiprone
Also written as “ONC206”, “ONC206: Dose 1” and “ONC206: Dose 2”.
Its studies are mostly in Central Nervous System Neoplasms · Paraganglioma · Meningioma, led by Jazz Pharmaceuticals.
Furthest: phase 2, since Dec 5, 20253 company-led studies, 3 open or runningNext primary completion: Mar 31, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jazz Pharmaceuticals | 33 open or running | phase 2since Dec 5, 2025 | Sep 1, 2020 | Mar 31, 2027phase 1 · NCT04541082 |
Also a collaborator on its studies: chimerix-inc.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 1, 2020First study: phase 1 study in Central Nervous System NeoplasmsFirst studyNCT04541082 · 35 enrolled · United States
- Dec 5, 2025Phase 2 study in ParagangliomaPhase 2 reachedNCT07282587 · 90 planned · United States
- Apr 10, 2026Phase 2 study in MeningiomaNCT07533942 · 30 planned · United States
- Oct 23, 2026Primary completion moved from 2026-07 to 2027-03-31Date moved laterphase 1 · +9 months · NCT04541082
Ahead
- Mar 31, 2027Primary completion: phase 1 study in Central Nervous System NeoplasmsNCT04541082
- Oct 25, 2028Primary completion: phase 2 study in MeningiomaNCT07533942
- Dec 15, 2028Primary completion: phase 2 study in ParagangliomaNCT07282587
TargetBeta
DRD2 →read by rule
“An orally bioavailable, selective bitopic dopamine receptor D2 (DRD2) antagonist and mitochondrial caseinolytic protease P (ClpP) agonist, ”NCIt, by rule
Other programs on DRD2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Aripiprazolerule | Otsuka | phase 4 | 131 |
| Risperidonerule | Johnson & Johnson | phase 4 | 111 |
| paliperidonerule | Johnson & Johnson | phase 4 | 106 |
| Olanzapinerule | Eli Lilly | phase 4 | 76 |
| brexpiprazolerule | Otsuka | phase 4 | 70 |
| rotigotinerule | UCB | phase 4 | 64 |
| lurasidonerule | Sumitomo Pharma | phase 4 | 52 |
| Pramipexolerule | Boehringer Ingelheim | phase 4 | 44 |
| iloperidonerule | Vanda Pharmaceuticals | phase 4 | 15 |
| Cabergolinerule | Changchun GeneScience Pharmaceutical | phase 4 | 8 |
| cariprazinerule | AbbVie | phase 3 | 41 |
| lumateperonerule | Johnson & Johnson | phase 3 | 25 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07533942Meningioma · United States | 2 | Recruiting | Oct 25, 2028 | 30 |
| NCT07282587Paraganglioma · United States | 2 | Recruiting | Dec 15, 2028 | 90 |
| NCT04541082Central Nervous System Neoplasms · United States | 1 | Active, not recruiting | Mar 31, 2027 | 35 |
How it is read
Names in the registry
- “ONC206”, 2 entries
- “ONC206: Dose 1”, 1 entry
- “ONC206: Dose 2”, 1 entry
- “JZP3507”, 1 entry
Conditions, from the studies’ own filings
- Central Nervous System Neoplasms, 1 study
- Paraganglioma, 1 study
- Meningioma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.